Abstract
Acute Hemorrhagic Conjunctivitis (AHC) has caused a significant outbreak in Pakistan in 2023, leading to a surge in cases across various cities. To gain insights into the genetic makeup of the virus responsible for the outbreak, the National Institute of Health, Islamabad conducted a study involving twenty individuals with suspected conjunctivitis in Islamabad. Five of these samples underwent whole-genome sequencing for the first-time in Pakistan, revealing Coxsackievirus A24 variant (CVA24v), genotype IV. Phylogenetic analysis revealed a higher homology (99.38-99.43%) with isolates from Zhongshan, China, in June 2023, with notable mutations concentrated in the 3D and VP1 regions. The sample also exhibited a 94% homology with 2015 France isolates. Comparing the 2023 study sequence with partial 2005 Pakistan sequences revealed divergence in the VP1 region, marked by three non-synonymous mutations (“H25P,” “I89V,” and “I90L”), while no mutation was found in the VP3 region. Notably, no intertypic recombination events were detected. This study underscores the significance of genomic surveillance for effective understanding and management of infectious disease outbreaks, offering crucial insights for public health interventions.
- Pink Eye infection
- Pakistan
- Outbreak
- Coxsackievirus A24 variant
- Acute Hemorrhagic Conjunctivitis
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
We gratefully acknowledge the New Variant Assessment Platform (NVAP), UK Health Security Agency (UKHSA) for their support of sequencing reagents.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Internal Review Board of the National Institute of Health (NIH), Islamabad. Informed consent was obtained from all subject involved in the study
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Sequence generated in the current study is submitted to the GenBank NCBI are available at https://www.ncbi.nlm.nih.gov/genbank/ under the accession numbers: OR633288.
